|Bid||38.58 x 2900|
|Ask||38.59 x 1200|
|Day's range||38.35 - 38.67|
|52-week range||33.26 - 42.68|
|Beta (5Y monthly)||0.38|
|PE ratio (TTM)||16.20|
|Earnings date||01 Feb 2017 - 06 Feb 2017|
|Forward dividend & yield||2.21 (5.76%)|
|Ex-dividend date||19 Aug 2021|
|1y target est||48.21|
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Dr. Arthur Caplan, NYU Langone Health, Division of Medical Ethics at NYU School of Medicine, joins Yahoo Finance to discuss the latest on the coronavirus vaccines and booster shots.
Shares of Vir Biotechnology (NASDAQ: VIR) were sinking 18.1% for the week as of the market close on Thursday. Vir was pulled down by the overall stock market sell-off earlier this week. It's best to avoid making investment decisions based on analysts' downgrades (and upgrades, for that matter).